Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Materialtyp: Artikel
Språk:engelska
Publicerad: Philipps-Universität Marburg 2023
Ämnen:
SARS-CoV-2
proteomics
COVID-19
Medizin
acute respiratory distress syndrome
Ruxolitinib
Medical sciences Medicine
Länkar:PDF-fulltext
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!
Publikationen im Open Access gefördert durch die UB

Liknande verk